International Clinical Trial: Biweekly versus standard Cisplatin and Gemcitabine for Elderly Patients with Advanced Biliary Tract Cancer (BCG65), a randomized-controlled trial

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (TCTR20251010002) titled 'Biweekly versus standard Cisplatin and Gemcitabine for Elderly Patients with Advanced Biliary Tract Cancer (BCG65), a randomized-controlled trial' on Oct. 10.

Study Type: Interventional

Study Design: Randomized

Primary Sponsor: N/A

Condition: Age at least 65 years old unresectable locally advanced or metastatic billiary tract carcinoma. Planned treatment with cisplatin and gemcitabine No prior exposure to cisplatin, carboplatin, or oxaliplatin, or if previously received, had been discontinued for at least 6 months Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 Adequate organ function ...